Using ctDNA to predict recurrence and response in colorectal cancer

Bookmark and Share
Published: 15 Jul 2019
Views: 678
Rating:
Save
Dr Aparna Parikh - Massachusetts General Hospital Cancer Center, Boston, USA

Dr Aparna Parikh speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about using cell-free circulating tumour DNA (ctDNA) to predict recurrence and response in colorectal cancer patients during adjuvant and neoadjuvant therapy.

She explains the method of genomic profiling they used to detect ctDNA after definitive therapy.

Dr Parikh concludes that not only can ctDNA be a marker of response to therapy, but that the kinetics of clearance can be indicative of time to recurrence.